Literature DB >> 10828626

Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis.

S Sato1, T Nagaoka, M Hasegawa, C Nishijima, K Takehara.   

Abstract

BACKGROUND: Serum KL-6 has been suggested to be a useful marker for the evaluation of interstitial lung disease activity.
OBJECTIVE: To determine the correlation between serum KL-6 levels and pulmonary fibrosis in patients with systemic sclerosis (SSc).
METHODS: Serum samples from patients with limited cutaneous SSc (lSSc; n = 19), diffuse cutaneous SSc (dSSc; n = 26) and normal individuals (n = 15) were examined by ELISA.
RESULTS: Serum KL-6 levels in SSc patients were significantly higher than those in normal controls. KL-6 levels in dSSc patients were significantly elevated compared with those in lSSc patients. Elevated KL-6 levels were associated with the presence of pulmonary fibrosis in SSc patients or dSSc patients. Furthermore, KL-6 levels inversely correlated with percentages of diffusion capacity of carbon monoxide and vital capacity in SSc patients or dSSc patients.
CONCLUSION: KL-6 may be a simple, serologic indicator for the severity of pulmonary fibrosis in SSc. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828626     DOI: 10.1159/000018382

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  13 in total

1.  Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation.

Authors:  T Ashida; M Higashishiba; Y Sumimoto; T Sano; H Miyazato; T Shimada; J Miyatake; K Kawanishi; Y Tatsumi; A Kanamaru
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

Review 2.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

Review 3.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 4.  Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.

Authors:  Kristin B Highland; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

5.  Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.

Authors:  Meihua Qiu; Xueyuan Nian; Lingling Pang; Pengfei Yu; Shenchun Zou
Journal:  Int J Rheum Dis       Date:  2021-08-21       Impact factor: 2.558

6.  Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.

Authors:  Audrey Benyamine; Xavier Heim; Noémie Resseguier; Daniel Bertin; Carine Gomez; Mikaël Ebbo; Jean-Robert Harlé; Gilles Kaplanski; Pascal Rossi; Nathalie Bardin; Brigitte Granel
Journal:  Rheumatol Int       Date:  2018-02-17       Impact factor: 2.631

Review 7.  A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Tracy J Doyle; Joyce S Lee; Paul F Dellaripa; James A Lederer; Eric L Matteson; Aryeh Fischer; Dana P Ascherman; Marilyn K Glassberg; Jay H Ryu; Sonye K Danoff; Kevin K Brown; Harold R Collard; Ivan O Rosas
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

8.  Biomarkers of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Juan Chen; Tracy J Doyle; Yongliang Liu; Rohit Aggarwal; Xiaoping Wang; Yonghong Shi; Sheng Xiang Ge; Heqing Huang; Qingyan Lin; Wen Liu; Yongjin Cai; Diane Koontz; Carl R Fuhrman; Maria F Golzarri; Yushi Liu; Hiroto Hatabu; Mizuki Nishino; Tetsuro Araki; Paul F Dellaripa; Chester V Oddis; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

9.  Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.

Authors:  Xiao-Yu Cao; Sha-Sha Hu; Dong Xu; Meng-Tao Li; Qian Wang; Yong Hou; Xiao-Feng Zeng
Journal:  Int J Rheum Dis       Date:  2018-12-28       Impact factor: 2.454

Review 10.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.